August 11th, 2017
•An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
Related Videos
Long-term High-Resolution Intravital Microscopy in the Lung with a Vacuum Stabilized Imaging Window
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Moving Upwards: A Simple and Flexible In Vitro Three-dimensional Invasion Assay Protocol
A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Mesenchymal Stem Cell Isolation from Pulp Tissue and Co-Culture with Cancer Cells to Study Their Interactions
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
In Vitro Assay to Study Tumor-macrophage Interaction
In Vitro Evaluation of Oncogenic Transformation in Human Mammary Epithelial Cells
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved